Skip to content

"Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma

Evaluation of Optimised Whole-body MRI Examinations Incorporating "Pseudo-scanner" Sequences (ZTE, "Zero Echo Time" AND Lava Flex) for the Detection of Bone Lesions in Multiple Myeloma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06988020
Acronym
MM-ZTE-II
Enrollment
45
Registered
2025-05-23
Start date
2025-04-22
Completion date
2027-11-01
Last updated
2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma Bone Disease

Keywords

bone, imaging, mri, multiple myeloma

Brief summary

Recent work has confirmed the diagnostic performance of pseudo-CT sequences for detecting osteolytic lesions. Their integration into whole body MRI (WB MRI) could transform the diagnostic approach to MM, by allowing a combined assessment of bone marrow involvement, tissue viability and osteolysis, during a single non-irradiating imaging examination. Since the preliminary work mentioned above, optimizations have been made to the pseudo-CT sequences, including the addition of deep learning (correcting noise in the images) and the correction of chemical shift artifact (linked to the coexistence of hydrated tissue and fatty tissue), which carry real hope of improving their diagnostic potential and accuracy.

Detailed description

Currently recommended imaging techniques for detecting bone lesions include whole-body MRI (WB-MRI), computed tomography (CT), and PET-CT. WB-MRI and PET-CT outperform CT for assessing treatment response, with WB-MRI already being the imaging modality of choice in many countries. However WB-MRI, the technique of choice for detecting bone marrow involvement, does not allow visualization of mineral bone, limiting its ability to accurately assess osteolysis. Zero Echo Time (ZTE) and Lava Flex Low Flip Angle (LF) MRI sequences represent a major advance, providing visualization of tissues at very short T2 relaxation times with resolution close to that of CT. These new sequences (known as pseudo-CT or pseudo-CT) offer for the first time the opportunity to study mineral bone by MRI, thus considerably increasing the diagnostic potential of this modality in MM.

Interventions

DEVICEMRI

Whole body MRI including ZTE sequences

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lead SponsorOTHER
General Electric
CollaboratorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patient with newly diagnosed multiple myeloma, for whom bone imaging is required for staging. * Recurrent patient after intensive treatment (high dose chemotherapy, bone marrow transplant, etc.). * Patient requiring a PET / CT considered as the technique of choice in these stages of the disease.

Exclusion criteria

* Implanted material incompatible with MRI. * Severe claustrophobia. * Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of the diagnostic performance of the different imaging protocolsthrough study completion, an average of 1 yearThe diagnostic performance of the different imaging protocols will be evaluated by analyzing the receptor efficiency function (ROC curve) and by estimating the Sensitivity (Se), Specificity (Sp), Positive Predictive Value (PPV), Negative Predictive Value (NPV) ) as well as the Predictive Accuracy (Acc) of the different imaging protocols.

Secondary

MeasureTime frameDescription
Comparison of Sensitivity (Se) and Predictive Precision (Acc) of the different imaging protocolsthrough study completion, an average of 1 yearMcNemar test on paired data. The Gold Standard will be determined by a panel of independent experts based on all available imaging techniques.

Countries

Belgium

Contacts

CONTACTFrédéric Lecouvet
frederic.lecouvet@saintluc.uclouvain.be+3227642793
CONTACTPerrine Triqueneaux
perrine.triqueneaux@saintluc.uclouvain.be
PRINCIPAL_INVESTIGATORFrédéric Lecouvet

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026